<DOC>
	<DOCNO>NCT02211326</DOCNO>
	<brief_summary>The purpose study determine whether international pharmacogenetic algorithm well standard initiation dose whether two algorithm suitable Chinese elderly patient .</brief_summary>
	<brief_title>Genotype-guided Warfarin Individualized Treatment</brief_title>
	<detailed_description>The study protocol multicenter , randomize , patient-blinded control trial , compare two approach among 864 enrol AF ( atrial fibrillation ) DVT ( deep venous thrombosis ) patient guide warfarin initial anticoagulation Chinese elderly patient : intervention group use algorithm International Warfarin Pharmacogenetic Consortium dose revision , control group use standard initiation dose ( 2.25 mg ) .The study hypothesis intervention group relative control group increase percentage time therapeutic INR ( international normalize ratio ) range first 3 months.This trial first prospective large-scale randomize control trial elder China . It great significance promote special crowd individualization anticoagulant home abroad .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Age ≥ 60 year old . Require warfarin therapy least 12 week . Diagnosed AF DVT target INR 1.52.5 . Willingness ability sign inform consent . Can communicate effectively complete trial . Current treatment coumarin . Have know stable dose . Have know CYP2C9 VKORC1 genotype . Expect accept treatment kind anticoagulant drug . Contraindications warfarin . Severe cognitive impairment would affect adherence therapy judge attend physician . Baseline INR≥1.5 Alcoholism substance abuse past 12 month . Blood transfusion bone marrow transplantation past two week . Severe hepatic renal dysfunction . History major bleed bleed disorder high risk blood coagulation . History positive hepatitis B antigen hepatitis C antibody Randomly assign . Hemoglobin less 1000 g/L platelet count &lt; 75×109 U/L total number white blood cell ( WBC ) &lt; 3×109 U/L . Prepare expect bleed occur invasive examination ( besides check routine endoscopy ) operation subject study period . Accept researchbased drug device Within 3 month randomly assign , program research treatment period research . Any following diagnosis condition subject : Active malignant tumor diagnose recent 5 year , except get adequate treatment non melanoma skin cancer noninvasive carcinoma situ original seat cervical cancer ; Cancer treatment drug , radiation and/or surgical treatment recent 5 year ; With apparent active disease infection ; Life expectancy＜6 month . If treat physician feel patient eligible clinical reason .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>AF DVT</keyword>
	<keyword>Age Over 60 Years , Acquired</keyword>
</DOC>